exposur
carbohydratebind
agent
cba
ie
mannosespecif
plant
lectin
hippeastrum
hybrid
agglutinin
galanthu
nivali
agglutinin
progress
select
mutant
strain
contain
nglycan
delet
envelop
result
resist
mutant
viru
strain
cba
exposur
mutant
viru
strain
mannosidas
inhibitor
dmj
result
enhanc
suppress
mutant
virusinduc
cytopath
cem
cell
cultur
moreov
combin
cba
concentr
show
poor
suppress
mutant
viru
replic
singl
drug
synergist
antivir
activ
dmj
observ
observ
argu
combin
exposur
cba
glycosyl
inhibitor
dmj
hiv
afford
pronounc
suppress
viru
replic
prior
cba
resist
develop
major
envelop
virus
contain
multipl
glycan
envelop
protein
case
ie
human
immunodefici
viru
hiv
hepat
c
viru
hcv
coronavirus
cov
influenza
viru
inf
envelop
extens
glycosyl
envelop
hiv
among
heavili
glycosyl
protein
known
protein
glycosyl
may
serv
multipl
function
includ
proper
fold
nascent
peptid
avoid
peptid
precipit
due
presenc
lipophyl
amino
acid
domain
protein
protect
breakdown
proteas
increas
molecular
divers
last
least
case
escap
immun
surveil
glycan
build
block
glcnac
man
glc
ad
asparagin
nativ
peptid
part
nglycosyl
motif
nxst
nglycan
process
aglucosidas
remov
termin
three
glucos
endoplasmat
reticulum
er
er
golgi
class
specif
hydrolyz
residu
catalys
trim
highmannos
chain
involv
four
mannos
residu
process
gener
man
glcnac
subsequ
action
glcnac
transferas
initi
complex
chain
format
yield
substrat
golgi
amannosidas
ii
trim
termin
residu
process
event
golgi
apparatu
eventu
lead
glycan
consist
wide
varieti
carbohydr
combin
thereof
sinc
mammalian
virus
use
host
cell
glycosyl
machineri
glycan
synthesi
modif
glycan
need
incorpor
envelop
glycoprotein
suggest
possibl
target
viral
envelop
glycoprotein
inhibit
certain
hostcel
glucosidas
low
level
affect
hostcel
viabil
alter
glycan
structur
viral
envelop
protein
may
result
decreas
viral
infect
fit
viru
assembl
andor
viru
particl
releas
hiv
infect
inde
shown
suppress
cell
cultur
viru
propag
presenc
aglucosidas
inhibitor
nbdnj
latter
drug
evalu
phase
ii
clinic
trial
antihiv
therapeut
hepat
b
viru
hbv
demonstr
nndnj
also
minor
extent
nbdnj
disrupt
proper
fold
effici
releas
viral
envelop
molecul
shown
nbdnj
could
reduc
viru
level
dosedepend
manner
sinc
transmembran
glycoprotein
hcv
import
host
cell
entri
sinc
proper
fold
calnexindepend
glucosidas
inhibitor
may
also
expect
affect
hcv
entri
infect
recent
shown
carbohydratebind
agent
cba
abl
forc
delet
part
glycan
envelop
attempt
escap
drug
pressur
mutant
viru
strain
display
differ
degre
phenotyp
sensit
cba
antivir
activ
depend
number
natur
glycan
delet
studi
want
investig
whether
concomit
combin
cba
glycosyl
inhibitor
dmj
abbrevi
cba
carbohydratebind
agent
hha
hippeastrum
hybrid
agglutinin
gna
galanthu
nivali
agglutinin
dmj
hiv
human
immunodefici
viru
hbv
hepat
b
viru
hcv
hepat
c
viru
er
endoplasmat
reticulum
wildtyp
mutant
glycandelet
strain
could
afford
superior
antivir
activ
ad
singl
drug
dmj
use
select
inhibit
result
accumul
highmannos
glycan
viral
envelop
glycoprotein
found
significantli
increas
sensit
mutant
viru
strain
inhibit
dmj
mark
potenti
antivir
efficaci
cba
coadminist
dmj
wildtyp
mutant
viru
strain
mannosespecif
plant
lectin
galanthu
nivali
gna
hippeastrum
hybrid
hha
deriv
purifi
plant
describ
dmj
obtain
sigmaaldrich
st
loui
mo
calbiochem
vwr
intern
haasrod
belgium
human
tlymphocyt
cem
cell
obtain
american
type
cultur
collect
manassa
va
cultiv
medium
supplement
fetal
bovin
serum
fb
biowittak
europ
vervier
belgium
mm
l
lglutamin
nahco
iii
b
provid
dr
rc
gallo
dr
popov
time
nation
cancer
institut
nci
nation
institut
health
nih
bethesda
md
mutant
viru
strain
obtain
character
describ
methodolog
antihiv
assay
describ
previous
briefli
cem
cell
cell
per
ml
suspend
fresh
cultur
medium
infect
ccid
per
ml
cell
suspens
infect
cell
suspens
transfer
micropl
well
mix
appropri
dilut
test
compound
incub
day
giant
cell
format
record
microscop
cem
cell
cultur
effect
concentr
ec
correspond
compound
concentr
requir
prevent
syncytium
format
virusinfect
cem
cell
cultur
drug
combin
experi
dmj
ad
cell
cultur
prior
addit
cba
viru
infect
drugexpos
cell
proper
control
experi
one
drug
none
drug
present
carri
similar
experiment
condit
data
repres
experi
shown
figur
cba
hha
gna
wildtyp
mutant
strain
antivir
activ
mannosidas
inhibitor
dmj
mannosespecif
plant
lectin
hha
gna
investig
wildtyp
iii
b
three
mutant
iii
b
strain
contain
varieti
glycan
delet
envelop
tabl
dmj
suppress
iii
b
induc
cytopath
cem
cell
cultur
concentr
high
lm
howev
dmj
evalu
antivir
activ
mutant
viru
strain
gain
measur
antivir
efficaci
dmj
inhibitori
ec
rang
lm
mutant
viru
strain
thu
cytopath
activ
mutant
viru
strain
invari
suppress
dmj
tabl
contrast
cba
hha
gna
show
ec
valu
low
lgml
wildtyp
iii
b
respect
markedli
lost
pronounc
suppress
activ
three
mutant
viru
strain
ec
lgml
tabl
thu
delet
glycan
clearli
compromis
antivir
activ
cba
wildtyp
cem
cell
cultur
effect
lm
dmj
inhibitori
activ
cba
hha
gna
wildtyp
replic
cem
cell
cultur
investig
fig
alreadi
mention
dmj
inhibitori
cytopath
concentr
use
lm
contrast
hha
fig
gna
fig
singl
drug
complet
prevent
cpe
cem
cell
cultur
concentr
low
lgml
lgml
hha
gna
inhibitori
respect
lgml
residu
inhibitori
effect
cba
observ
interestingli
coadministr
dmj
hha
gna
markedli
potenti
antivir
glycan
delet
nglycosyl
site
indic
determin
ref
notat
refer
presenc
glycan
contain
wildtyp
sequenc
notat
refer
presenc
mixtur
wildtyp
mutat
sequenc
viru
isol
b
c
complextyp
glycan
highmannos
type
glycan
efficaci
cba
inhibitori
activ
lgml
hha
increas
presenc
dmj
upon
coadministr
dmj
lgml
gna
lower
hha
gna
concentr
pronounc
antivir
activ
notic
cba
neither
absenc
presenc
dmj
fig
mutant
strain
cem
cell
cultur
three
differ
strain
shown
contain
sever
nglycan
delet
envelop
tabl
expos
gna
hha
presenc
varieti
dmj
concentr
lm
dmj
combin
gna
fig
dmj
act
synergist
combin
cba
exampl
lgml
gna
show
poor
antivir
efficaci
cs
fig
panel
cs
fig
panel
b
becam
protect
virusinduc
cytopath
effect
presenc
lm
dmj
protect
presenc
lm
dmj
synergist
effect
also
seen
dmj
sn
gna
administ
higher
concentr
rang
lm
fig
panel
c
similar
synergist
activ
dmj
note
mutant
viru
strain
combin
hha
fig
panel
b
c
surprisingli
lower
gna
hha
concentr
lm
combin
dmj
rather
antagonist
activ
observ
phenomenon
consist
seen
hha
gna
presenc
differ
dmj
concentr
fig
neither
cba
lm
dmj
lm
prove
inhibitori
cem
cell
prolifer
whether
administ
cell
cultur
singl
drug
combin
data
shown
drug
combin
also
inhibitori
effect
cell
metabol
sinc
radiolabel
thymidin
uridin
leucin
incorpor
cem
cell
dna
rna
protein
measur
affect
glycosyl
inhibitor
dmj
target
er
golgi
mannosidas
trim
man
glcnac
glycan
er
aglucosidas
ii
remov
three
termin
glucos
unit
nglycan
glc
man
glcnac
block
result
amount
highmannos
type
glycan
structur
glycoprotein
markedli
increas
presenc
dmj
sinc
trim
process
highmannos
glycan
hybridor
complextyp
glycan
larg
prevent
dmjmediat
blockad
sinc
cba
gna
hha
known
specif
bind
andor
mannos
oligom
structur
could
reason
higher
amount
highmannos
type
glycan
may
allow
cba
concomittantli
bind
higher
amount
glycan
envelop
consequ
may
exert
pronounc
antivir
activ
dmjtreat
virusinfect
cell
observ
inde
potenti
activ
hha
gna
presenc
dmj
concentr
exert
antivir
activ
use
singl
drug
thu
concomitt
administr
glycosyl
inhibitor
dmj
cba
cell
cultur
may
potenti
antivir
activ
mannosespecif
cba
interestingli
wherea
wildtyp
viru
infect
replic
effici
proceed
presenc
high
ie
lm
dmj
concentr
ec
lm
mutant
strain
contain
multipl
delet
nglycan
gain
sensit
inhibitori
activ
inhibitor
dmj
cem
cell
cultur
wherea
dmj
effect
lm
parent
wildtyp
viru
could
inde
inhibit
mutant
viru
infect
ec
rang
lm
least
lower
dmj
concentr
mutant
viru
strain
show
glycan
delet
put
nglycosyl
site
delet
preferenti
occur
highmannos
type
glycan
site
tabl
glycan
delet
mutant
strain
result
mark
phenotyp
resist
hha
gna
cba
could
assum
dmj
convert
least
part
remain
glycan
mutant
highmannosetyp
glycan
structur
make
vulner
interact
cba
consequ
increas
antivir
activ
would
expect
upon
coadministr
dmj
phenomenon
inde
observ
occur
hivinfect
cell
cultur
interestingli
similar
phenomenon
observ
occur
pradimicin
high
mannosetyp
glycanbind
antibiot
expos
mammalian
cell
pretreat
dmj
experiment
condit
cell
express
high
level
high
mannosetyp
oligosaccharid
becom
sensit
prma
result
apoptosi
induct
apoptosi
induct
observ
prmaexpos
cell
cultur
pretreat
dmj
thu
combin
use
cba
dmj
enabl
partial
restor
phenotyp
sensit
mutant
strain
cba
result
argu
combin
administr
cba
dmj
wildtyp
viru
phenotyp
resist
develop
may
expect
slow
dmj
present
cba
treatment
slight
consist
observ
antagonist
activ
observ
dmj
combin
lowest
cba
concentr
rather
puzzl
molecular
basi
phenomenon
yet
unclear
gener
concern
therapeut
applic
inhibitor
target
cellular
enzym
inhibitor
dmj
inde
inhibit
cellular
glycosyl
enzym
virusinfect
cell
may
compromis
proper
viral
glycopeptid
format
may
also
deleteri
effect
glycoprotein
noninfect
cell
howev
therapi
drug
casu
glycosyl
inhibitor
necessari
aim
ablat
enzym
activ
rather
use
modul
enzym
activ
involv
glycosyl
sinc
envelop
glycoprotein
hiv
among
highest
glycosyl
glycoprotein
current
known
high
function
requir
highmannos
type
glycan
may
assum
moder
attenu
activ
may
pronounc
deleteri
impact
synthesi
viral
envelop
glycoprotein
cellular
glycoprotein
allow
certain
degre
select
inhibitor
proper
vivo
experi
reveal
therapeut
efficaci
feasibl
drug
conclus
mannosidas
inhibitor
dmj
found
potenti
inhibitori
activ
cba
wildtyp
administr
dmj
cell
cultur
infect
mutant
strain
contain
nglycan
delet
envelop
render
mutant
viru
suscept
inhibitori
activ
dmj
moreov
dmj
partial
revers
phenotyp
resist
cba
mutant
viru
strain
three
phenomena
may
argu
investig
glycosidas
inhibitor
limit
dmj
use
combin
cba
aim
potenti
antivir
activ
cba
delay
resist
develop
may
develop
cba
drug
pressur
